Latest Hotspot

Inmagene Reports Promising Phase 2a Results for IMG-007, a Nondepleting Anti-OX40 Antibody, in Atopic Dermatitis Treatment

8 May 2024
3 min read

Inmagene Biopharmaceuticals, a biotech firm at the clinical stage focused on creating unique therapies for immune and inflammatory conditions, recently disclosed encouraging preliminary results from a Phase 2a study of IMG-007 in individuals suffering from AD.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

IMG-007, a nondepleting anti-OX40 monoclonal antibody, has been engineered to mute its antibody-dependent cellular cytotoxicity (ADCC) and extend its half-life. Previous Phase 1 research involving a single dose administered to healthy volunteers confirmed that IMG-007 was safe and well-tolerated, showing no signs of fever or chills, which aligns with the suppressed ADCC activity.

Moreover, the antibody displayed delayed elimination from the body with a half-life of 31 days at the doses expected for therapeutic use. This extended half-life facilitates less frequent administration schedules, potentially every 12 weeks for initial therapy and more sparingly for ongoing management in treating atopic dermatitis (AD).

"The interruption of OX40-OX40L interactions presents a promising method for AD management," comments Jonathan Silverberg, M.D., Ph.D., a Dermatology Professor at The George Washington University School of Medicine and Health Sciences. "IMG-007's specific targeting mechanism for the OX40 receptor, paired with an extended half-life and non-T-cell depleting qualities, offers a foremost advantage in safety and treatment convenience, including quarterly dosing."

Yufang Lu, M.D., Ph.D., Chief Medical Officer at Inmagene, shares enthusiastic remarks about the treatment's effectiveness, "The short 4-week treatment period already exhibited significant results. Ongoing and future trials using IMG-007 consistently in AD patients may enhance these outcomes even further," Lu states. "Considering the critical function of the OX40-OX40L pathway in various immune and inflammatory diseases, IMG-007 holds potential across multiple clinical conditions. Efforts continue to fast-track its development for AD using a subcutaneous approach."

Additionally, IMG-007 is under investigation in a Phase 2a study targeting AD, with final outcomes expected by Q3 2024. It is also part of a global clinical trial for adult patients with alopecia areata (AA), with preliminary data expected in Q4 2024.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of May 7, 2024, there are 60 investigational drugs for the OX40 target, including 75 indications, 73 R&D institutions involved, with related clinical trials reaching 111, and as many as 26607 patents.

IMG-007 targets OX40 and is being investigated for its potential in treating immune system diseases, congenital disorders, as well as skin and musculoskeletal diseases. Currently in Phase 1/2 of clinical development globally, IMG-007 has received IND approval in China.

图形用户界面, 文本, 应用程序

描述已自动生成

What ADC-related progress will Lepu Biopharma reveal at the ASCO conference?
Hot Spotlight
4 min read
What ADC-related progress will Lepu Biopharma reveal at the ASCO conference?
8 May 2024
Lepu Biopharma is an innovative biopharmaceutical company focused on the field of oncology treatment, particularly in targeted therapy and immunotherapy.
Read →
Boehringer Ingelheim reports encouraging outcomes from the initial global study on diabetic macular ischemia
Latest Hotspot
3 min read
Boehringer Ingelheim reports encouraging outcomes from the initial global study on diabetic macular ischemia
8 May 2024
Boehringer Ingelheim has revealed encouraging results from its HORNBILL Phase I/IIa trial for BI 764524.
Read →
What is the difference between the CDER and CBER divisions of the FDA?
"What" Series
2 min read
What is the difference between the CDER and CBER divisions of the FDA?
8 May 2024
The U.S. FDA encompasses multiple centers including key ones like the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).
Read →
BioAtla gets FDA nod to start trials of BA3361, a CAB targeting Nectin-4 in diverse cancers
Latest Hotspot
3 min read
BioAtla gets FDA nod to start trials of BA3361, a CAB targeting Nectin-4 in diverse cancers
8 May 2024
BioAtla Receives FDA Approval to Begin Trials of BA3361, a Conditionally Active Biologic (CAB) Targeting Nectin-4 in Various Cancers.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.